We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267).
1. What are the major unmet needs in current neoadjuvant chemotherapy regimes for women undergoing dual HER2 blockade for stage II–III HER2-positive breast cancer? (0:06)
2. Could you give us a brief overview of the TRAIN-2 study and its major findings? (1:08)
3. What have the long-term findings of this study taught us about the use of anthracyclines? (4:56)
4. What questions will the TRAIN-3 study address? (5:48)
5. What other approaches should be investigated in this treatment setting? (7:10)
Speaker disclosure: Anna van der Voort has no financial or non-financial relationships or activities to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
Share this Video
Related Videos In Breast Cancer
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Javier Cortes, SABCS 2020 – Pembrolizumab in Triple-negative Breast Cancer
touchONCOLOGY joins Dr Javier Cortes at the San Antonio Breast Cancer Symposium (SABCS) 2020, to discuss the data being presented around the KEYNOTE-355 study and the potential of pembrolizumab as a treatment for triple-negative breast cancer (Clinical Trial Identifier: NCT02819518). The abstract ‘Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!